Zepzelca
Registration timeline
The following table summarises the key steps and dates for this application.
This evaluation was facilitated through Project Orbis, an initiative of the United States (US) Food and Drug Administration (FDA) Oncology Center of Excellence (OCE). Under this project, the FDA and the TGA collaboratively reviewed the application. This innovative evaluation process provided a framework for process alignment and management of evaluation issues in real-time across jurisdictions.
Each regulator agency maintained its regulatory process to make independent decisions about the approval (market authorisation).
| Description | Date |
|---|---|
| Designation - Orphan | 17 February 2020 |
| Designation - Provisional | 29 April 2020 |
| Submission dossier accepted and first round evaluation commenced | 2 June 2020 |
| First round evaluation completed | 2 November 2020 |
| Sponsor provides responses on questions raised in first round evaluation | 21 December 2020 |
| Second round evaluation completed | 12 February 2021 |
| Delegate's overall benefit-risk assessment | 8 September 2021 |
| Sponsor's pre-Advisory Committee response | Not applicable |
| Advisory Committee meeting | Not applicable |
| Registration decision (Outcome) | 10 September 2021 |
| Completion of administrative activities and registration on ARTG | 13 September 2021 |
| Number of working days from submission dossier acceptance to registration decision* | 153 |
*Statutory timeframe for standard applications is 255 working days
(S)-lactic acid, sucrose and sodium hydroxide
The recommended dose is 3.2 mg/m2 by intravenous infusion over 60 minutes, repeated once every 21 days until disease progression or unacceptable toxicity.
Only administer Zepzelca to patients with an absolute neutrophil count above 1.5 x 109/L, and a platelet count above 100 x 109/L.
For further information refer to the Product Information.
Zepzelca (lurbinectedin) was approved for the following therapeutic use:
Zepzelca is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) that has progressed on or after prior platinum-containing therapy. This indication was approved via the provisional approval pathway, based on objective response rate and duration of response in a single arm trial. Continued approval for this indication depends on verification and description of clinical benefit in a confirmatory trial.
- Zepzelca (lurbinectedin) is to be included in the Black Triangle Scheme. The Product Information (PI) and Consumer Medicine Information (CMI) for Zepzelca must include the black triangle symbol and mandatory accompanying text for the products entire period of provisional registration.
The lurbinectedin core European Union (EU)-risk management plan (RMP) (version 0.2, dated 15 January 2020, data lock point 17 April 2020), with Australian specific annex (ASA) (version 0.3, dated September 2021), included with Submission PM-2020-02181-1-4, and any subsequent revisions, as agreed with the TGA will be implemented in Australia.
An obligatory component of risk management plans is routine pharmacovigilance. Routine pharmacovigilance includes the submission of periodic safety update reports (PSURs).
Unless agreed separately between the supplier who is the recipient of the approval and the TGA, the first report must be submitted to TGA no later than 15 calendar months after the date of the approval letter. The subsequent reports must be submitted no less frequently than annually from the date of the first submitted report until the period covered by such reports is not less than three years from the date of the approval letter, or the entire period of provisional registration, whichever is longer.
The reports are to at least meet the requirements for PSURs as described in the European Medicines Agency's Guideline on Good Pharmacovigilance Practices (GVP) Module VII-Periodic safety update report (Rev 1), Part VII.B Structures and processes. Note that submission of a PSUR does not constitute an application to vary the registration. Each report must have been prepared within ninety calendar days of the data lock point for that report.
Confirmatory trial data (as identified in the sponsor's plan to submit comprehensive clinical data on the safety and efficacy of the medicine before the end of the 6 years that would start on the day that registration would commence) must be provided.
Specifically, the sponsor must conduct studies as described in the clinical study plan in version 0.3 (September 2021) of the ASA. The following study report(s) should be submitted to TGA:
- PM1183-C-008-21, by first quarter of 2026
Further guidance for sponsors is available on the TGA website.
- For all injectable products the PI must be included with the product as a package insert.